Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous Stem Cell Transplantation With Nivolumab in Patients With Multiple Myeloma

Trial Profile

Autologous Stem Cell Transplantation With Nivolumab in Patients With Multiple Myeloma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Melphalan (Primary) ; Nivolumab (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use

Most Recent Events

  • 06 May 2024 Planned End Date changed from 1 Dec 2023 to 30 Dec 2024.
  • 06 May 2024 Planned primary completion date changed from 1 Dec 2022 to 30 Dec 2024.
  • 06 May 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top